How Scots-Knight was paid
$2.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Other | Total |
|---|---|---|---|---|
| Dr. Denise Scots-KnightChief Executive Officer | $642,917 | $2,001,019 | $88,603 | $2,732,540 |
| Charles SermonGeneral Counsel | $472,935 | $635,475 | $63,502 | $1,171,912 |
| Christine FoxChief Financial Officer | $444,672 | $635,475 | $52,530 | $1,132,677 |
What changed and why
- $2.7MDr. Denise Scots-Knight received total compensation of $2,732,540 for fiscal year 2025.
- 3.0%Named executive officers received salary increases of 3.0 percent in 2025.
- No cash bonuses were paid for 2025 due to clinical trial results.
- 50%Executives received market value stock options in lieu of cash bonuses equal to 50 percent of their target.
- All executive compensation is denominated in pounds sterling and converted to U.S. dollars.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.